ArticleClinical proteomics2025
Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment.
Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeAlopecia Areata (AA) is an inflammatory non-cicatricial alopecia with a high prevalence. Some patients with AA show an inferior response to treatment. To find key proteins in AA, Genome-wide association study data from three cohorts were analyzed using Mendelian randomization (MR) method. PATIENTS AND
methodsThe gene expression of the identified proteins was further evaluated and compared between AA and healthy samples from two single-cell RNA datasets (GSE212447 and GSE233906). A cell model was also built to validate the findings. Autodock Vina and GROMACS, were also employed to search for ingredients from traditional Chinese medicine(TCM) that interacted with the identified protein.
resultsThree proteins, DEFB1, HGFAC, and CYB5D2, were identified as potential drug targets. The altered gene expression in lesional samples of AA patients was consistent with the promoting or protective effects of identified proteins on the disease. The overexpression of risk factor DEFB1 upregulated the RNA and protein expression of MICA in HaCaT cells. The TCM ingredient cimigenol was found to interact with DEFB1 via molecular docking, and molecular dynamics simulations confirmed the stability of this interaction.
conclusionDEFB1 is a potential drug target with promising prospects for the development of novel drugs for treating AA. The TCM ingredient, cimigenol, is a promising drug for AA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.